Analysts at Canaccord Genuity initiated coverage on Histogenics Corporation HSGX with a Buy rating.
The target price for Histogenics is set to $16.50.
Histogenics' shares rose 0.45% to close at $11.05 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
